Globally, people lost confidence in the importance of routine childhood vaccines against lethal diseases like measles and polio, a survey finds; advocates say that the proposed price of about $50 a kit for naloxone could be too expensive; Bipartisan Senate legislation introduced this week would cap insulin at $35 per month for those with private insurance.
Faith Lost in Childhood Vaccines, Says UNICEF
A new report from UNICEF suggests that people around the world lost confidence in the necessity of routine childhood vaccines against deadly diseases like measles and polio during the COVID-19 pandemic, according to NBC News. Public perception of vaccines for children lowered between 2019 and 2021 in 52 of 55 surveys. The organization said that the data was a “worrying warning signal” of increasing vaccine hesitancy and misinformation, shrinking trust in governments, and political polarization. This was after the largest sustained backslide in childhood immunization in a generation occurred during pandemic disruptions.
Advocates Worry Naloxone Price Will Reduce Access
Naloxone (Narcan), the nasal spray that reverses opioid overdoses, will retail for “less than $50” per each 2 pack of 4-milligram sprays, said the manufacturer on Thursday, inciting criticism that the price would make it inaccessible for many during a drug crisis killing over 100,000 people per year, reported The Washington Post. Drug manufacturer Emergent BioSolutions made the announcement weeks after the FDA approved the drug without a prescription to make it easy to buy and plentiful. However, advocates worry that price might be a barrier.
Senate Legislation Would Cap Insulin at $35/Month for Those With Private Insurance
Bipartisan Senate legislation presented this week would cap the cost of insulin at $35 per month for those with private insurance, according to CNBC. The bill drafted by Senators Jeanne Shaheen, D-N.H., and Susan Collins, R-Maine, comes 2 months following President Joe Biden’s call on Congress during his SCOTUS address to broaden the insulin price cap to the millions of people with diabetes who have private insurance. The President’s Inflation Reduction Act capped the price of insulin at $35 for seniors on Medicare when it became law in 2022, but a push to include people with private insurance deteriorated in Congress last year due to Republican opposition.
Urticaria Diagnosis Challenged by Overlapping Pruritic Skin Conditions
April 23rd 2025Urticaria is complicated to diagnose by its symptomatic overlap with other skin conditions and the frequent misclassification in literature of distinct pathologies like vasculitic urticaria and bullous pemphigus.
Read More
New Research Challenges Assumptions About Hospital-Physician Integration, Medicare Patient Mix
April 22nd 2025On this episode of Managed Care Cast, Brady Post, PhD, lead author of a study published in the April 2025 issue of The American Journal of Managed Care®, challenges the claim that hospital-employed physicians serve a more complex patient mix.
Listen
Personalized Care Key as Tirzepatide Use Expands Rapidly
April 15th 2025Using commercial insurance claims data and the US launch of tirzepatide as their dividing point, John Ostrominski, MD, Harvard Medical School, and his team studied trends in the use of both glucose-lowering and weight-lowering medications, comparing outcomes between adults with and without type 2 diabetes.
Listen
ACOs’ Focus on Rooting Out Fraud Aligns With CMS Vision Under Oz
April 23rd 2025Accountable care organizations (ACOs) are increasingly playing the role of data sleuths as they identify and report trends of anomalous billing in hopes of salvaging their shared savings. This mission dovetails with that of CMS, which under the new administration plans to prioritize rooting out fraud, waste, and abuse.
Read More